Author:
Wang Jun,Zhang Xue-ying,Kang Yan-hong,Zhang Yun,Chen Xin-yi,Zhou Jia-li,Ma Wei
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Hemostasis and thrombosis Group, Hematology Society, Chinese Medical Association. Chinese expert consensus on diagnosis and treatment of primary immune thrombocytopenia in adults (2016 edition). Chin J Hematol (Chin) 2016;37:89–92.
2. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160:1630–1638.
3. Thrombosis and hemostasis Group, Society of Hematology, Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of primary immune thrombocytopenia in adults (2020 edition). Chin J Hematol (Chin) 2020;41:617–623.
4. Deshayes S, Godeau B. Second-line and beyond: treatment options for primary persistent and chronic immune thrombocytopenia. Platelets 2020;31:291–292.
5. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood 2017;129:2829–2835.